Page last updated: 2024-08-24

gemcitabine and Epithelial Ovarian Cancer

gemcitabine has been researched along with Epithelial Ovarian Cancer in 36 studies

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's24 (66.67)24.3611
2020's12 (33.33)2.80

Authors

AuthorsStudies
Ahmad, M; Alharbi, H; Aloahd, MS; Alrashed, MM; Alshehry, AS1
Bowering, V; Chang, K; Dhani, NC; Karakasis, K; Kavak, N; Lheureux, S; Madariaga, A; Mitchell, SA; Oza, AM; Pittman, T; Quintos, J; Ramsahai, J; Wang, L; Welch, SA1
Ambrosio, AJ; Birrer, MJ; Bradley, C; Konstantinopoulos, PA; Krasner, CN; Matulonis, UA; Penson, RT; Whalen, CA1
Arakawa, A; Goto, M; Hori, K; Ito, K; Kaneda, M; Kawabata, A; Kaya, R; Kondo, E; Motohashi, T; Nagasawa, T; Nakagawa, M; Nasu, H; Nishio, S; Park, J; Shimokawa, M; Suzuki, J; Tashima, L; Tsubamoto, H; Yamada, K; Yanagida, S1
Eguchi, S; Hara, K; Honjoh, H; Miyamoto, Y; Mori, M; Nara, K; Nishijima, A; Osuga, Y; Sone, K; Taguchi, A; Takada, T; Tojima, Y; Yamamoto, T1
Bayram, E; Guzel, AB; Khatib, G; Kuçukgoz-Gulec, U; Paydas, S; Vardar, MA1
Ates, O; Buyukkor, M; Tay, F1
Bastière-Truchot, L; Berger, R; Berton-Rigaud, D; Cardona, A; Colombo, N; du Bois, A; González Martin, A; Greimel, E; Grischke, EM; Hilpert, F; Kroep, JR; Kurzeder, C; Lorusso, D; Lück, HJ; Martinez-Garcia, J; Mirza, MR; Ottevanger, P; Pardo, B; Rau, J; Redondo, A; Selle, F; Vergote, I1
Bell, R; Bell-McGuinn, K; Buderath, P; Campbell, R; Farrington, DL; Fiorica, J; Golden, L; Hamilton, A; Heitz, F; Lee, CM; Moore, KN; Pitou, C; Powell, M; Sehouli, J; Teneriello, M; Vergote, I; Wenham, RM; Zhang, W1
Bun, S; Kato, MK; Kato, T; Miyasaka, N; Shimoi, T; Tamura, K; Yonemori, K; Yunokawa, M1
Barroilhet, LM; Brown, J; Darus, C; Duska, LR; Jelovac, D; McGuire, WP; Moore, KN; Petroni, GR; Secord, AA; Varhegyi, N1
Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS1
Bartos, P; Bartunkova, J; Chovanec, J; Cibula, D; Fucikova, J; Galluzzi, L; Hassan, HIB; Hein, A; Hraska, M; Hrnciarova, T; Kieszko, D; Klat, J; Knapp, P; Madry, R; Mallmann, P; Markowska, J; Melichar, B; Minar, L; Pecen, L; Pluta, M; Rob, L; Spacek, J; Spisek, R; Streb, J; Valha, P; Wimberger, P1
Fernandes Junior, HJ; Graziani, SR; Kalil Filho, R; Maranhão, RC; Morikawa, AT; Van Eyll, BM; Vital, CG1
Bonetti, A; Giuliani, J1
Chung, V; Cristea, M; Diamond, DJ; Ellenhorn, JDI; Eng, M; Frankel, P; Hardwick, NR; Kaltcheva, T; Kilpatrick, J; Kos, F; Leong, L; Morgan, R; Ruel, C; Tinsley, R; Tsai, W; Wilczynski, S1
Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T1
Dohrmann, T; Izbicki, JR; Jaenicke, F; Kutup, A; Mahner, S; Müller, V; Vashist, YK1
Altevogt, P; Bretz, NP; Fogel, M; Hazin, J; Herr, I; Keller, S; Moldenhauer, G; Perne, C; Salnikov, AV; Schlange, T1
Arena, MG; Barba, M; Corrado, G; Di Lauro, L; Giannarelli, D; Mariani, L; Maugeri-Saccà, M; Paoletti, G; Pizzuti, L; Sergi, D; Tomao, F; Tomao, S; Vici, P; Vincenzoni, C; Vizza, E1
Asna, N; Grisaru, D; Inbar, M; Matcejevsky, D; Safra, T; Shpigel, S; Veizman, A1
Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y1
Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q1
Chanpanitkitchot, S; Khunnarong, J; Pataradool, K; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T1
Byun, JH; Hong, SH; Jung, KH; Kim, HG; Kim, HY; Kim, KH; Lee, HJ; Lee, NR; Lee, S; Lee, SC; Park, KH; Rha, SY; Woo, IS; Yun, J1
Matsumoto, K; Onda, T; Yaegashi, N1
Aghajanian, C; Blank, SV; Goff, B; Husain, A; Nycum, LR; Wang, YV1
Enas, NH; Friberg, LE; Gueorguieva, I; Zecchin, C1
Almorsy, W; Elshebeiny, M1
Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK1
Burkholder, TL; Chen, MD; Gill, JF; Gordon, AN; Hines, J; Homesley, HD; Janicek, MF; Lim, PC; McMeekin, S; Obasaju, CK; Orlando, M; Tai, DF; Teneriello, M; Vaccarello, L; Wang, Y; Zhao, L1
Camoriano, JK; Colon-Otero, G; Erlichman, C; Glaser, G; Haluska, P; Hendrickson, AE; Ivy, SP; Karnitz, LM; Kaufmann, SH; Oberg, AL; Peethambaram, PP1
Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K1
Byun, HJ; Kim, BR; Park, SY; Rho, SB; Yoo, R1
Kitao, A; Matsumoto, K1

Reviews

1 review(s) available for gemcitabine and Epithelial Ovarian Cancer

ArticleYear
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids

2015

Trials

16 trial(s) available for gemcitabine and Epithelial Ovarian Cancer

ArticleYear
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian ca
    Gynecologic oncology, 2022, Volume: 167, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fatigue; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum

2022
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
    The oncologist, 2023, 03-17, Volume: 28, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Recurrence; Treatment Outcome

2023
Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601.
    Anti-cancer drugs, 2023, 08-01, Volume: 34, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms

2023
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2019, Volume: 29, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Progression-Free Survival; Receptor, ErbB-3; RNA, Messenger; Topotecan

2019
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
    Gynecologic oncology, 2020, Volume: 156, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Imidazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Progression-Free Survival; Pyridines; Young Adult

2020
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
    Gynecologic oncology, 2020, Volume: 157, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Indazoles; Middle Aged; Peritoneal Neoplasms; Pyrimidines; Sulfonamides

2020
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
    Gynecologic oncology, 2021, Volume: 162, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Middle Aged; Neoplasm Staging; Ovarian Neoplasms

2021
Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.
    Medical oncology (Northwood, London, England), 2017, Volume: 34, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Lipids; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols

2017
p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 03-15, Volume: 24, Issue:6

    Topics: Adult; Aged; Cancer Vaccines; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platinum; T-Lymphocytes; Treatment Outcome; Tumor Suppressor Protein p53

2018
Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.
    Journal of experimental & clinical cancer research : CR, 2013, Aug-08, Volume: 32, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Salvage Therapy

2013
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult

2014
Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
    Gynecologic oncology, 2015, Volume: 136, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Republic of Korea; Vinblastine; Vinorelbine

2015
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
    Gynecologic oncology, 2015, Volume: 139, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Survival Rate

2015
Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer.
    British journal of clinical pharmacology, 2016, Volume: 82, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Gemcitabine; Humans; Models, Biological; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Survival Analysis

2016
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
    Gynecologic oncology, 2011, Volume: 123, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult

2011
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
    Gynecologic oncology, 2012, Volume: 124, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cohort Studies; Deoxycytidine; Female; Gemcitabine; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Rate

2012

Other Studies

19 other study(ies) available for gemcitabine and Epithelial Ovarian Cancer

ArticleYear
MiR-624-5p enhances NLRP3 augmented gemcitabine resistance via EMT/IL-1β/Wnt/β-catenin signaling pathway in ovarian cancer.
    Journal of reproductive immunology, 2022, Volume: 150

    Topics: beta Catenin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; NLR Family, Pyrin Domain-Containing 3 Protein; Ovarian Neoplasms; Wnt Signaling Pathway

2022
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer.
    International journal of clinical oncology, 2023, Volume: 28, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Gemcitabine; Humans; Irinotecan; Ovarian Neoplasms; Polyethylene Glycols

2023
Comparison of the effectiveness of liposomal doxorubicin and gemcitabine in patients with platinum-sensitive recurrent ovarian cancer receiving third-line chemotherapy.
    European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life; Reproducibility of Results; Retrospective Studies

2023
Efficacy and Safety of Combined Chemotherapy Regimens with Bevacizumab in Platinum-sensitive Ovarian Cancers.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2023, Volume: 33, Issue:9

    Topics: Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms

2023
Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.
    Journal of cancer research and clinical oncology, 2020, Volume: 146, Issue:5

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Drug Resistance, Neoplasm; Evidence-Based Medicine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Survival Rate

2020
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2020, Volume: 30, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan

2020
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin

2017
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.
    European journal of gynaecological oncology, 2017, Volume: 38, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan

2017
Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-20, Volume: 31, Issue:12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Female; Gastric Fistula; Gemcitabine; Humans; Intestinal Fistula; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms

2013
Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas.
    British journal of cancer, 2013, Apr-16, Volume: 108, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; CD24 Antigen; Cell Growth Processes; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Macrophages; Mice; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Transplantation, Heterologous; Xenograft Model Antitumor Assays

2013
The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
    Anti-cancer drugs, 2014, Volume: 25, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies

2014
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
    European journal of gynaecological oncology, 2013, Volume: 34, Issue:6

    Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2013
Treatment outcomes of gemcitabine in refractory or recurrent epithelial ovarian cancer patients.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Treatment Outcome

2014
Singapore Cancer Network (SCAN) Guidelines for Front-Line Systemic Therapy of Newly Diagnosed Advanced Epithelial Ovarian Cancer.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Parenteral; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Polyethylene Glycols; Singapore

2015
Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy.
    Journal of the Egyptian National Cancer Institute, 2016, Volume: 28, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum

2016
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome

2011
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.
    International journal of clinical oncology, 2013, Volume: 18, Issue:1

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids

2013
sMEK1 enhances gemcitabine anti-cancer activity through inhibition of phosphorylation of Akt/mTOR.
    Apoptosis : an international journal on programmed cell death, 2012, Volume: 17, Issue:10

    Topics: Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphoprotein Phosphatases; Phosphorylation; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2012
[Treatment of recurrent ovarian cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 4

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Reoperation; Topotecan

2012